The following serious adverse reactions are discussed in greater detail in other sections of the labeling:
- Complex Sleep Behaviors [see WARNINGS AND PRECAUTIONS (5.1)]
- CNS-Depressant Effects and Next-Day Impairment [see WARNINGS AND PRECAUTIONS (5.2)]
- Severe Anaphylactic and Anaphylactoid Reactions [see WARNINGS AND PRECAUTIONS (5.4)]
- Abnormal Thinking and Behavior Changes [see WARNINGS AND PRECAUTIONS (5.5)]
- Withdrawal Effects [see WARNINGS AND PRECAUTIONS (5.9)]
6.1 Clinical Trials Experience
Associated with Discontinuation of Treatment
In 3-week clinical trials in adults and elderly patients (> 65 years), 3.5% (7/201) patients receiving zolpidem tartrate extended-release tablets 6.25 or 12.5 mg discontinued treatment due to an adverse reaction as compared to 0.9% (2/216) of patients on placebo. The reaction most commonly associated with discontinuation in patients treated with zolpidem tartrate extended-release tablets were somnolence (1%).
In a 6-month study in adult patients (18 to 64 years of age), 8.5% (57/669) of patients receiving zolpidem tartrate extended-release tablets 12.5 mg as compared to 4.6% on placebo (16/349) discontinued treatment due to an adverse reaction. Reactions most commonly associated with discontinuation of zolpidem tartrate extended-release tablets included anxiety (anxiety, restlessness or agitation) reported in 1.5% (10/669) of patients as compared to 0.3% (1/349) of patients on placebo, and depression (depression, major depression or depressed mood) reported in 1.5% (10/669) of patients as compared to 0.3% (1/349) of patients on placebo.
Data from a clinical study in which selective serotonin reuptake inhibitor (SSRI)- treated patients were given zolpidem revealed that four of the seven discontinuations during double-blind treatment with zolpidem (n=95) were associated with impaired concentration, continuing or aggravated depression, and manic reaction; one patient treated with placebo (n=97) was discontinued after an attempted suicide.
Most Commonly Observed Adverse Reactions in Controlled Trials
During treatment with zolpidem tartrate extended-release tablets in adults and elderly at daily doses of 12.5 mg and 6.25 mg, respectively, each for three weeks, the most commonly observed adverse reactions associated with the use of zolpidem tartrate extended-release tablets were headache, next-day somnolence, and dizziness.
In the 6-month trial evaluating zolpidem tartrate extended-release tablets 12.5 mg, the adverse reaction profile was consistent with that reported in short-term trials, except for a higher incidence of anxiety (6.3% for zolpidem tartrate extended-release tablets versus 2.6% for placebo).
Adverse Reactions Observed at an Incidence of ≥ 1% in Controlled Trials
The following tables enumerate treatment-emergent adverse reactions frequencies that were observed at an incidence equal to 1% or greater among patients with insomnia who received zolpidem tartrate extended-release tablets in placebo-controlled trials. Events reported by investigators were classified utilizing the MedDRA dictionary for the purpose of establishing event frequencies. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice, in which patient characteristics and other factors differ from those that prevailed in these clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigators involving related drug products and uses, since each group of drug trials is conducted under a different set of conditions. However, the cited figures provide the physician with a basis for estimating the relative contribution of drug and nondrug factors to the incidence of side effects in the population studied.
The following tables were derived from results of two placebo-controlled efficacy trials involving zolpidem tartrate extended-release tablets. These trials involved patients with primary insomnia who were treated for 3 weeks with zolpidem tartrate extended-release tablets at doses of 12.5 mg (Table 1) or 6.25 mg (Table 2), respectively. The tables include only adverse reactions occurring at an incidence of at least 1% for zolpidem tartrate extended-release tablets patients and with an incidence greater than that seen in the placebo patients.
* Reactions reported by at least 1% of patients treated with zolpidem tartrate extended-release tablets and at greater frequency than in the placebo group. | ||
† Hallucinations included hallucinations NOS as well as visual and hypnagogic hallucinations. | ||
‡ Memory disorders include: memory impairment, amnesia, anterograde amnesia. | ||
Body System Adverse Reaction* | Zolpidem Tartrate Extended-Release Tablets, 12.5 mg (N = 102) | Placebo |
Infections and infestations | ||
Influenza | 3 | 0 |
Gastroenteritis | 1 | 0 |
Labyrinthitis | 1 | 0 |
Metabolism and nutrition disorders | ||
Appetite disorder | 1 | 0 |
Psychiatric disorders | ||
Hallucinations † | 4 | 0 |
Disorientation | 3 | 2 |
Anxiety | 2 | 0 |
Depression | 2 | 0 |
Psychom*otor retardation | 2 | 0 |
Binge eating | 1 | 0 |
Depersonalization | 1 | 0 |
Disinhibition | 1 | 0 |
Euphoric mood | 1 | 0 |
Mood swings | 1 | 0 |
Stress symptoms | 1 | 0 |
Nervous system disorders | ||
Headache | 19 | 16 |
Somnolence | 15 | 2 |
Dizziness | 12 | 5 |
Memory disorders‡ | 3 | 0 |
Balance disorder | 2 | 0 |
Disturbance in attention | 2 | 0 |
Hypoesthesia | 2 | 1 |
Ataxia | 1 | 0 |
Paresthesia | 1 | 0 |
Eye disorders | ||
Visual disturbance | 3 | 0 |
Eye redness | 2 | 0 |
Vision blurred | 2 | 1 |
Altered visual depth perception | 1 | 0 |
Asthenopia | 1 | 0 |
Ear and labyrinth disorders | ||
Vertigo | 2 | 0 |
Tinnitus | 1 | 0 |
Respiratory, thoracic and mediastinal disorders | ||
Throat irritation | 1 | 0 |
Gastrointestinal disorders | ||
Nausea | 7 | 4 |
Constipation | 2 | 0 |
Abdominal discomfort | 1 | 0 |
Abdominal tenderness | 1 | 0 |
Frequent bowel movements | 1 | 0 |
Gastroesophageal reflux disease | 1 | 0 |
Vomiting | 1 | 0 |
Skin and subcutaneous tissue disorders | ||
Rash | 1 | 0 |
Skin wrinkling | 1 | 0 |
Urticaria | 1 | 0 |
Musculoskeletal and connective tissue disorders | ||
Back pain | 4 | 3 |
Myalgia | 4 | 0 |
Neck pain | 1 | 0 |
Reproductive system and breast disorders | ||
Menorrhagia | 1 | 0 |
General disorders and administration site conditions | ||
Fatigue | 3 | 2 |
Asthenia | 1 | 0 |
Chest discomfort | 1 | 0 |
Investigations | ||
Blood pressure increased | 1 | 0 |
Body temperature increased | 1 | 0 |
Injury, poisoning and procedural complications | ||
Contusion | 1 | 0 |
Social circ*mstances | ||
Exposure to poisonous plant | 1 | 0 |
* Reactions reported by at least 1% of patients treated with zolpidem tartrate extended-release tablets and at greater frequency than in the placebo group. | ||
† Memory disorders include: memory impairment, amnesia, anterograde amnesia. | ||
Body System Adverse Reaction * | Zolpidem Tartrate Extended-Release Tablets, 6.25 mg (N=99) | Placebo |
Infections and infestations | ||
Nasopharyngitis | 6 | 4 |
Lower respiratory tract infection | 1 | 0 |
Otitis externa | 1 | 0 |
Upper respiratory tract infection | 1 | 0 |
Psychiatric disorders | ||
Anxiety | 3 | 2 |
Psychom*otor retardation | 2 | 0 |
Apathy | 1 | 0 |
Depressed mood | 1 | 0 |
Nervous system disorders | ||
Headache | 14 | 11 |
Dizziness | 8 | 3 |
Somnolence | 6 | 5 |
Burning sensation | 1 | 0 |
Dizziness postural | 1 | 0 |
Memory disorders † | 1 | 0 |
Muscle contractions involuntary | 1 | 0 |
Paresthesia | 1 | 0 |
Tremor | 1 | 0 |
Cardiac disorders | ||
Palpitations | 2 | 0 |
Respiratory, thoracic and mediastinal disorders | ||
Dry throat | 1 | 0 |
Gastrointestinal disorders | ||
Flatulence | 1 | 0 |
Vomiting | 1 | 0 |
Skin and subcutaneous tissue disorders | ||
Rash | 1 | 0 |
Urticaria | 1 | 0 |
Musculoskeletal and connective tissue disorders | ||
Arthralgia | 2 | 0 |
Muscle cramp | 2 | 1 |
Neck pain | 2 | 0 |
Renal and urinary disorders | ||
Dysuria | 1 | 0 |
Reproductive system and breast disorders | ||
Vulvovagin*l dryness | 1 | 0 |
General disorders and administration site conditions | ||
Influenza like illness | 1 | 0 |
Pyrexia | 1 | 0 |
Injury, poisoning and procedural complications | ||
Neck injury | 1 | 0 |
Dose Relationship for Adverse Reactions
There is evidence from dose comparison trials suggesting a dose relationship for many of the adverse reactions associated with zolpidem use, particularly for certain CNS and gastrointestinal adverse events.
Other Adverse Reactions Observed during the Premarketing Evaluation of Zolpidem Tartrate Extended-Release Tablets
Other treatment-emergent adverse reactions associated with participation in zolpidem tartrate extended-release tablets studies (those reported at frequencies of <1%) were not different in nature or frequency to those seen in studies with immediate-release zolpidem tartrate, which are listed below.
Adverse Events Observed during the Premarketing Evaluation of Immediate-Release Zolpidem Tartrate
Immediate-release zolpidem tartrate was administered to 3,660 subjects in clinical trials throughout the U.S., Canada, and Europe. Treatment-emergent adverse events associated with clinical trial participation were recorded by clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals experiencing treatment-emergent adverse events, similar types of untoward events were grouped into a smaller number of standardized event categories and classified utilizing a modified World Health Organization (WHO) dictionary of preferred terms.
The frequencies presented, therefore, represent the proportions of the 3,660 individuals exposed to zolpidem, at all doses, who experienced an event of the type cited on at least one occasion while receiving zolpidem. All reported treatment-emergent adverse events are included, except those already listed in the table above of adverse events in placebo-controlled studies, those coding terms that are so general as to be uninformative, and those events where a drug cause was remote. It is important to emphasize that, although the events reported did occur during treatment with AMBIEN, they were not necessarily caused by it.
Adverse events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are defined as those occurring in greater than 1/100 subjects; infrequent adverse events are those occurring in 1/100 to 1/1,000 patients; rare events are those occurring in less than 1/1,000 patients.
Frequent: dry mouth. Infrequent: increased sweating, pallor, postural hypotension, syncope. Rare: abnormal accommodation, altered saliva, flushing, glaucoma, hypotension, impotence, increased saliva, tenesmus.
Body as a Whole:
Frequent: asthenia. Infrequent: chest pain, edema, falling, fever, malaise, trauma. Rare: allergic reaction, allergy aggravated, anaphylactic shock, face edema, hot flashes, increased ESR, pain, restless legs, rigors, tolerance increased, weight decrease.
Cardiovascular System:
Infrequent: cerebrovascular disorder, hypertension, tachycardia. Rare: angina pectoris, arrhythmia, arteritis, circulatory failure, extrasystoles, hypertension aggravated, myocardial infarction, phlebitis, pulmonary embolism, pulmonary edema, varicose veins, ventricular tachycardia.
Central and Peripheral Nervous System:
Frequent: ataxia, confusion, drowsiness, drugged feeling, euphoria, insomnia, lethargy, lightheadedness, vertigo. Infrequent: agitation, decreased cognition, detached, difficulty concentrating, dysarthria, emotional lability, hallucination, hypoesthesia, illusion, leg cramps, migraine, nervousness, paresthesia, sleeping (after daytime dosing), speech disorder, stupor, tremor. Rare: abnormal gait, abnormal thinking, aggressive reaction, apathy, appetite increased, decreased libido, delusion, dementia, depersonalization, dysphasia, feeling strange, hypokinesia, hypotonia, hysteria, intoxicated feeling, manic reaction, neuralgia, neuritis, neuropathy, neurosis, panic attacks, paresis, personality disorder, somnambulism, suicide attempts, tetany, yawning.
Gastrointestinal System:
Frequent: diarrhea, dyspepsia, hiccup. Infrequent: anorexia, constipation, dysphagia, flatulence, gastroenteritis. Rare: enteritis, eructation, esophagospasm, gastritis, hemorrhoids, intestinal obstruction, rectal hemorrhage, tooth caries.
Hematologic and Lymphatic System:
Rare: anemia, hyperhemoglobinemia, leukopenia, lymphadenopathy, macrocytic anemia, purpura, thrombosis.
Infrequent: infection. Rare: abscess herpes simplex herpes zoster, otitis externa, otitis media.
Liver and Biliary System:
Infrequent: abnormal hepatic function, increased SGPT. Rare: bilirubinemia, increased SGOT.
Metabolic and Nutritional:
Infrequent: hyperglycemia, thirst. Rare: gout, hypercholesteremia, hyperlipidemia, increased alkaline phosphatase, increased BUN, periorbital edema.
Musculoskeletal System:
Infrequent: arthritis. Rare: arthrosis, muscle weakness, sciatica, tendinitis.
Reproductive System:
Infrequent: menstrual disorder, vaginitis. Rare: breast fibroadenosis, breast neoplasm, breast pain.
Respiratory System:
Frequent: sinusitis. Infrequent: bronchitis, coughing, dyspnea. Rare: bronchospasm, respiratory depression, epistaxis, hypoxia, laryngitis, pneumonia.
Skin and Appendages:
Infrequent: pruritus. Rare: acne, bullous eruption, dermatitis, furunculosis, injection-site inflammation, photosensitivity reaction, urticaria.
Special Senses:
Frequent: diplopia, vision abnormal. Infrequent: eye irritation, eye pain, scleritis, taste perversion, tinnitus. Rare: conjunctivitis, corneal ulceration, lacrimation abnormal, parosmia, photopsia.
Urogenital System:
Frequent: urinary tract infection. Infrequent: cystitis, urinary incontinence. Rare: acute renal failure, dysuria, micturition frequency, nocturia, polyuria, pyelonephritis, renal pain, urinary retention.
6.2 Postmarketing Experience
The following adverse reactions have been identified during postapproval use of zolpidem tartrate extended-release tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Liver and biliary system
Acute hepatocellular, cholestatic or mixed liver injury with or without jaundice (i.e., bilirubin >2x ULN, alkaline phosphatase ≥2x ULN, transaminase ≥5x ULN). Psychiatric disorders: delirium.